gut.bmj15d
Integration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer
Formalin-fixed paraffin-embedded tumour samples (n=8) were subjected to spatial transcriptomics analysis using the 10x Genomics 10x Visium platform and the libraries ... CRC patients ranged from 30 to ...
10x Genomics: Lower Cost Innovation May Drive A Rebound
Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...
Yahoo Finance27d
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics ... robust new product roadmap for its Visium and Xenium portfolios, extending ...
Stockhouse27d
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
In 2024, 10x Genomics launched its groundbreaking Visium HD product, increasing the resolution of the Visium platform by over three orders of magnitude. Now compatible with FFPE, Fresh Frozen and ...
Business Insider27d
10x Genomics unveils roadmap at AGBT general meeting
At the Advances in Genome Biology and Technology, AGBT, General Meeting, 10x Genomics (TXG ... unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance ...
abc2726d
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
In 2024, 10x Genomics launched its groundbreaking Visium HD product, increasing the resolution of the Visium platform by over three orders of magnitude. Now compatible with FFPE, Fresh Frozen and ...
Yahoo Finance27d
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology ...
Seeking Alpha3d
TXG 10x Genomics, Inc.
10x Genomics, Inc., a life science technology company ... and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein ...
ETF Daily News6d
10x Genomics, Inc. (NASDAQ:TXG) Receives Consensus Rating of “Hold” from Analysts
Shares of NASDAQ:TXG opened at $10.34 on Friday. The stock has a market capitalization of $1.26 billion, a P/E ratio of -6.80 and a beta of 1.93. 10x Genomics has a 1-year low of $9.27 and a 1 ...
The Harvard Crimson27d
Harvard, 10x Genomics Settle Patent Dispute With Vizgen
Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used ...
The Victoria Advocate19d
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
ETF Daily News16d
10x Genomics (NASDAQ:TXG) Price Target Lowered to $15.00 at Citigroup
10x Genomics has a 1 year low of $9.27 and a 1 year high of $44.21. The firm’s fifty day simple moving average is $13.75 and its 200 day simple moving average is $16.55. 10x Genomics (NASDAQ ...